Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Progenics Pharmaceuticals, Inc. (PGNX)

-NasdaqGS
3.50 Down 0.06(1.69%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Sep 30, 2013Jun 30, 2013Mar 31, 2013
Total Revenue 2,968   867   1,801   2,226  
Cost of Revenue253  91  153  70  
Gross Profit 2,715   776   1,648   2,156  
Operating Expenses
Research Development7,201  7,913  10,068  8,721  
Selling General and Administrative3,956  3,123  3,416  4,314  
Non Recurring316  73  119  116  
Others165  179  318  277  
Total Operating Expenses11,638  11,288  13,921  13,428  
Operating Income or Loss (8,923) (10,512) (12,273) (11,272)
Income from Continuing Operations
Total Other Income/Expenses Net10  12  10  14  
Earnings Before Interest And Taxes(8,913)(10,500)(12,263)(11,258)
Interest Expense -   -   -   -  
Income Before Tax(8,913)(10,500)(12,263)(11,258)
Income Tax Expense(362) -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(8,551)(10,500)(12,263)(11,258)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (8,551) (10,500) (12,263) (11,258)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (8,551) (10,500) (12,263) (11,258)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.